{
    "title": "112_s3237",
    "content": "The \"Accelerating the End of Breast Cancer Act of 2012\" establishes a commission with specific duties, membership, and evaluation processes. It also authorizes funding and includes a termination clause. The findings section outlines the rationale for the Act. The findings section of the \"Accelerating the End of Breast Cancer Act of 2012\" highlights the increasing prevalence of breast cancer, its impact on women globally, the high mortality rate due to metastasis, the significant economic burden of breast cancer care, and the lack of substantial progress in the past 40 years. Despite the increasing prevalence of breast cancer and its significant impact, there has been little improvement in the incidence, morbidity, and mortality rates over the past 40 years. Establishment of the Commission to Accelerate the End of Breast Cancer (referred to as the \"Commission\") with a mission to address the stagnant rates of breast cancer incidence, morbidity, and mortality. The Commission's mission is to help end breast cancer by 2020. Its duties include identifying opportunities for prevention, recommending projects in primary prevention and metastasis, promoting innovative ideas, and accelerating scientific advances not prioritized by the Federal Government. The Commission aims to achieve its mission of ending breast cancer by 2020 by identifying underdeveloped research areas, fostering collaborations, and submitting a strategic vision to the President and Congress within 6 months of its establishment. The Commission aims to end breast cancer by 2020 through research and collaborations. An annual report is submitted to the President, Congress, and the public by January 15, detailing activities and funding expenditures. The Commission aims to end breast cancer by 2020 through research and collaborations. An annual report is submitted to the President, Congress, and the public by January 15, detailing activities and funding expenditures. SEC. 5. MEMBERSHIP. The Commission, composed of up to 10 members appointed by the President with Senate approval, represents varied disciplines in biomedical research, outside the field, and includes educated patient advocates. The Commission, composed of up to 10 members appointed by the President with Senate approval, represents varied disciplines in biomedical research, outside the field, and includes educated patient advocates. The members are trained, knowledgeable, and prepared to participate in decision-making processes in science and medicine. The representation of membership categories includes appointing individuals to represent specific categories as outlined in the paragraphs. Initial members of the Commission must be appointed within 60 days of the enactment of the Act. The Commission, consisting of up to 10 members appointed by the President with Senate approval, must be appointed within 60 days of the Act's enactment. Each member serves a 3-year term, can be reappointed, and a quorum requires three members. Vacancies are filled for the remainder of the predecessor's term. SEC. 6. CHAIRPERSON; PROGRAM MANAGERS. The Chairperson of the Commission appointed under section 5(a) must be designated by the President and have qualifications related to managing areas of study on ending breast cancer by January 1, 2020. Responsibilities include approving study areas based on innovation and developing criteria for the Commission. The Chairperson of the Commission may appoint program managers to oversee areas of study, develop criteria for assessing success, terminate ineffective study areas, and appoint necessary staff to aid in achieving the Commission's mission. The Commission is responsible for recommending novel proposals, projects, and collaborations focused on breast cancer prevention and metastasis. They also identify innovative ideas and opportunities, work with other Federal agencies to maximize investment, and stimulate collaborative projects. The Commission aims to maximize Federal investment and stimulate collaborative projects by convening workshops, building collaborations, identifying areas of study, leveraging resources, and carrying out approved functions necessary to fulfill its mission. The Commission aims to monitor the progress of areas of study and recommend restructure or termination. SEC. 7. COORDINATION AND NONDUPLICATION. The Commission will coordinate its activities with other government agencies to avoid duplication. SEC. 8. EVALUATION OF THE COMMISSION. SEC. 8. EVALUATION OF THE COMMISSION. The President will have the Institute of Medicine evaluate the Commission's progress after 3 years, recommending whether it should continue or end, and sharing lessons learned. The \"Accelerating the End of Breast Cancer Fund\" is established in the Treasury of the United States to be administered by the Chairperson for the purpose of carrying out this section. Appropriations of $8,000,000 for fiscal year 2012, $12,000,000 for each of fiscal years 2013 and 2014, and necessary sums for each fiscal year thereafter until the Commission is terminated are authorized. None of the appropriated amounts shall be used for laboratory or pilot plant operations. The Commission is set to terminate on June 1, 2020."
}